Key result
MitraClip linked to ~62% lower risk of 24-month death or HF hospitalization vs. medical therapy.
Observational (n=71)
No
Answers are grounded in this paper and cite their sources.
Demonstrates reduced heart failure hospitalizations with MitraClip versus medical therapy in patients with cardiac resynchronization therapy, indicating delayed composite adverse events.
Forty patients (56%) were treated with the Mitraclip System (MitraClip group) and 31 patients (44%) only with medical therapy (no-MitraClip group). MitraClip group presented higher surgical risk than no-MitraClip group, as older age, chronic kidney disease, higher NYHA functional class and lower left ventricular ejection fraction. At 24-month no differences in all-cause mortality were detected between the two groups (Kaplan-Meier curves log-rank p = 0.947), although the MitraClip group presented lower rate of HF hospitalizations than the no-MitraClip group (log-rank p = 0.048). After adjustment for confounding factors, time to HF hospitalization or death was significantly delayed in MitraClip group (hazard ratio: 0.38; p-value 0.018).
No takes yet. Share an insight, caveat, or question.
Cirasa et al. (2019) conducted an observational in Heart failure with cardiac resynchronization therapy (CRT) and residual moderate-to-severe functional mitral regurgitation (FMR) (n=71). Percutaneous mitral valve repair with MitraClip System vs. Optimal medical therapy alone (no-MitraClip group) was evaluated on Composite of all-cause death or heart failure hospitalizations at 24-month follow-up (HR 0.38, 95% CI 0.17-0.85, p=0.018). MitraClip therapy delayed the composite of all-cause death or HF hospitalization at 24 months compared to medical therapy alone after multivariable adjustment.
Synapse has enriched 10 related papers. Consider them for comparative context: